FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
Clinical trials for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) explained in plain language.
Never miss a new study
Get alerted when new FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) trials appear
Sign up with your email to follow new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
FSHD drug trial halted midway: what happened?
Disease control TerminatedThis study tested a drug called losmapimod for people with a rare muscle-weakening disease called FSHD. The goal was to see if the drug could slow muscle loss and improve arm function over 48 weeks. About 260 adults with FSHD were randomly assigned to receive either losmapimod or…
Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
Phase: PHASE3 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental drug losmapimod tested for rare muscle disease
Disease control TerminatedThis phase 2 trial tested the drug losmapimod in 76 adults with FSHD, a genetic condition that causes progressive muscle weakness. Participants took either losmapimod or a placebo for 48 weeks to see if the drug was safe and could help control the disease. The study was terminate…
Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
Phase: PHASE2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC